Media Articles Related to Xigris (Drotrecogin Alfa)
Leading doctors warn that sepsis deaths will not be curbed without radical rethink of research strategy
Source: Blood / Hematology News From Medical News Today [2015.04.21]
Leading doctors warn that medical and public recognition of sepsis - thought to contribute to between a third and a half of all hospital deaths - must improve if the number of deaths from this...
Inflammatory factor IL-3 may play essential role in development of sepsis
Source: Allergy News From Medical News Today [2015.03.16]
Targeting IL-3 controlled pathways may help treat dangerous inflammatory reactionA new study finds that Interleukin-3 (IL-3), an inflammatory factor most associated with allergic reactions...
Source: MedicineNet Cellulitis Specialty [2015.02.09]
Category: Diseases and Conditions
Created: 2/6/2009 12:00:00 AM
Last Editorial Review: 2/9/2015 12:00:00 AM
Erectile dysfunction drugs could protect liver from sepsis-induced damage, says Pitt team
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2015.02.02]
Drugs that are on the market to treat erectile dysfunction (ED) could have another use--they might be able to protect the liver from damage caused by sepsis, a systemic inflammatory response to...
Neonatal Sepsis (Sepsis Neonatorum)
Source: MedicineNet Gonorrhea In Women Specialty [2014.12.09]
Title: Neonatal Sepsis (Sepsis Neonatorum)
Category: Doctor's Views
Created: 3/4/2009 12:00:00 AM
Last Editorial Review: 12/9/2014 12:00:00 AM
Published Studies Related to Xigris (Drotrecogin Alfa)
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. 
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). 
INTRODUCTION: Serial alterations in protein C levels appear to correlate with disease severity in patients with severe sepsis, and it may be possible to tailor severe sepsis therapy with the use of this biomarker. The purpose of this study was to evaluate the dose and duration of drotrecogin alfa (activated) treatment using serial measurements of protein C compared to standard therapy in patients with severe sepsis... CONCLUSIONS: The study met its primary objective of increased protein C levels in patients receiving alternative therapy demonstrating that variable doses and/or duration of drotrecogin alfa (activated) can improve protein C levels, and also provides valuable information for incorporation into potential future studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00386425.
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [2008.01]
OBJECTIVE:: To compare characteristics and outcomes of patients treated with drotrecogin alfa (activated) (DrotAA) in clinical practice to those treated in a phase III randomized controlled trial (PROWESS)... CONCLUSIONS:: Patients treated in clinical practice differed from those in PROWESS. Patients were younger, had more comorbidities, had greater severity of illness, and had longer mean time from severe sepsis onset to the start of DrotAA. Hospital mortality for patients treated within 1 day of severe sepsis onset was similar to DrotAA-treated PROWESS patients. While the low number of serious bleeding events precludes a definitive assessment, the observed incidence of serious bleeding events in clinical practice patients was numerically higher than in DrotAA-treated PROWESS patients.
My brother has severe sepsis Should he receive Xigris(R)? [2007.12]
Six years ago, a publication in a quite well known scientific medical journal brought hope and a good dose of optimism to sepsis therapy and the critical care community. For the first time, a careful randomized controlled trial in patients with severe sepsis or septic shock seemed to show a clearly beneficial effect of a new drug, i.e...
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). [2007.09.01]
RATIONALE: Patients with severe sepsis frequently receive prophylactic heparin during drotrecogin alfa (activated) (DrotAA) treatment due to risk of venous thromboembolic events (VTEs). Biological plausibility exists for heparin to reduce DrotAA efficacy and/or increase bleeding. OBJECTIVES: Primary: demonstrate in adult patients with severe sepsis receiving DrotAA treatment that 28-day mortality was equivalent for patients treated with concomitant prophylactic heparin compared with placebo; secondary: safety and VTE incidence... CONCLUSIONS: Compared with placebo, concomitant prophylactic heparin was not equivalent, did not increase 28-day mortality, and had an acceptable safety profile in patients with severe sepsis receiving DrotAA. Heparin discontinuation should be carefully weighed in patients considered for DrotAA treatment. XPRESS clinical trial registered with www.clinicaltrials.gov (NCT 00049777). The study ID numbers are 6743; F1K-MC-EVBR.
Clinical Trials Related to Xigris (Drotrecogin Alfa)
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis [Completed]
The purposes of this study are to determine:
1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their
condition more often or recover faster than children who do not receive drotrecogin alfa
2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with
3. The side effects that might be associated with drotrecogin alfa (activated)
administration to children with severe sepsis.
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study [Completed]
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation [Completed]
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood
cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for
bone marrow transplant (BMT).
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated) [Recruiting]
Protein C is a protein that is involved in your body's ability to clot blood. In this trial,
patients with severe sepsis and low protein C levels will receive drotrecogin alfa
(activated) at the normal, approved dose and time of administration [24mcg/kg/hour for 96
hours] or will receive the normal, approved dose or higher doses than the approved dose for a
longer administration time. After the drug administration is complete, the protein C levels
from the patients receiving the normal, approved dose will be compared to protein C levels
from patients receiving the normal, approved dose or higher dose for a longer duration to
determine if the protein C levels improve faster if given higher dose and/or longer
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion [Completed]
The purpose of this study is to determine whether continued administration of Drotrecogin
Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion
period - results in a more rapid resolution of hypotension in severe septic patients.
Reports of Suspected Xigris (Drotrecogin Alfa) Side Effects
Brain Death (2),
Finger Amputation (2),
Brain Oedema (2),
Immune System Disorder (2),
Septic Shock (2),
Disseminated Intravascular Coagulation (1),
Cerebral Haemorrhage (1),
Multi-Organ Failure (1),
Myocardial Infarction (1), more >>